Several challenges hinder the implementation of PTA. These include:
Cost: Continuing to provide an investigational drug can be expensive for sponsors. Regulatory issues: Different countries have different regulations regarding PTA, complicating global trials. Supply limitations: Limited production capacity can restrict the availability of the drug. Liability concerns: Sponsors may be wary of potential legal risks associated with providing unapproved treatments.
